SCHEMBL22802458

SCHEMBL22802458

COc1ccc2c(c1S(=O)(=O)Cl)CCCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
KAT7 O95251 1/20 0.38
KAT6B Q8WYB5 1/20 0.38
KAT6A Q92794 1/20 0.38
KAT5 Q92993 1/20 0.38
KAT8 Q9H7Z6 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
HSD11B1 P28845 1/20 0.36
HSD17B2 P37059 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
CES1 P23141 3/20 0.36
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RBP1 P09455 1/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172616 0.84 PTGES2 (0.39) HTR2AHTR2CHTR2BKAT7KAT6B
SCHEMBL31172838 0.81 PTGES2 (0.41) HTR2AHTR2CHTR2BKAT7KAT6B
SCHEMBL3920720 0.80 CES1 (0.42) ALDH1A1CES1LMNASMN1; SMN2KDM4E
SCHEMBL38653524 0.78 LMNA (0.36) HTR2AHTR2CHTR2BALDH1A1MAPT
SCHEMBL29469794 0.73 HSD11B1 (0.52) ALDH1A1MAPTHSD11B1HSD17B2KMT2A
SCHEMBL21872141 0.73 HSD11B1 (0.52) ALDH1A1MAPTHSD11B1HSD17B2KMT2A
SCHEMBL17770807 0.73 KDM4E (0.46) HTR2AHTR2CHTR2BALDH1A1MAPT
SCHEMBL16527162 0.73 HTR2C (0.65) HTR2AHTR2CHTR2BALDH1A1MAPT
SCHEMBL25319903 0.72 LMNA (0.41) HTR2AHTR2CHTR2BALDH1A1MAPT
SCHEMBL21596884 0.72 TUBB4A (0.38) ALDH1A1MAPTMEN1KMT2ATRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2026-03-05 US disclosed
EP-4299135-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-08-06 EP disclosed
US-12371425-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2025-07-29 US disclosed
EP-3986890-B9 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-04-16 EP disclosed
CN-114364672-B Benzisoxazole sulfonamide derivatives 辉瑞大药厂 2024-09-06 CN disclosed
EP-4299135-A2 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2024-01-03 EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 EP disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-11492346-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2022-11-08 US disclosed
EP-3986890-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2022-04-27 EP disclosed
CN-114364672-A Benzisoxazole sulfonamide derivatives 辉瑞大药厂 2022-04-15 CN disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 WO disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 US disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 US disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371425-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR HTR2A 4425/4885HTR2C 3816/4885HTR2B 3453/4885
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR HTR2A 4436/4885HTR2C 3815/4885HTR2B 3534/4885
US-11492346-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR HTR2A 4425/4885HTR2C 3816/4885HTR2B 3453/4885
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives KAT8, KAT5, KAT7 HTR2A 4530/4885HTR2C 3885/4885HTR2B 4245/4885
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR HTR2A 4425/4885HTR2C 3816/4885HTR2B 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.